AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 272 min read$RGEN

Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations

Repligen (RGEN) reported Q3 2026 revenue of $209.3M, beating estimates by 1.1% and growing 10.9% YoY. Adjusted EPS of $0.53 beat estimates by 14.6%. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Operating margin decreased to -14.1% from 8.9% YoY, while free cash flow margin fell to 18.1% from 23%.

Original reporting
finance.yahoo.com
Published Oct 27, 2026, 11:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RGENBullishMed
01

Why it matters

The earnings beat and guidance raise expectations for near‑term revenue growth, supporting a bullish stance.

02

Market read

Earnings beat and guidance raise make RGEN a short‑term buying candidate.

03

What to watch

Potential headwinds from slower macro demand for biotech consumables.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Repligen (NASDAQ:RGEN) is a biotech company providing protein‑A purification and chromatography products.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Repligen reported Q3 2026 results beating revenue and EPS estimates and raised full-year revenue and EPS guidance.

Expected impact

likely upward pressure as investors price in the beat and raised outlook

Evidence & confidence

Both earnings beat and guidance lift are fresh primary disclosures, providing a clear catalyst for short-term buying.

Market effects

Sector

Biotech tools sector may see modest uplift from Repligen's performance.

Regional

U.S. biotech stocks could benefit in early trading.

Global

Limited to investors tracking small‑cap biotech earnings.

Counterpoint

What could challenge this read

Some analysts may view the modest revenue lift as insufficient given valuation.

Key entities

  • Company
    Repligen

    Biotech tools provider reporting Q3 2026 results.

Read at source← All news

StoryRepligen posts record Q3 revenue, beats earnings and lifts FY2026 guidance after BioLife acquisition

Also covered by

6 outlets

Related articles

OCT 27
$RGENHigh

Repligen Corp (RGEN) Q3 2026 Earnings Call Highlights: Record Revenue, Raised Guidance

Repligen Corp (RGEN) reported Q3 2026 revenue of $209M, up 12.5% organically, and raised 2026 guidance. Chromatography and proteins grew over 40%, while filtration declined 11%. BioLife acquisition is expected to be $0.05 accretive in 2027. Capital equipment orders increased mid-teens YoY, but revenue lags due to slow customer decisions. Inflationary pressures and product mix headwinds impacted margins. The company recorded a $41M intangible asset impairment.

finance.yahoo.com2 min
OCT 27
$RGENMedAI 8/10

Repligen Corporation Q3 2026 Earnings Call Summary

Repligen Corporation reported Q3 2026 revenue of $209M, up 12.5% organically, driven by proteins and chromatography. Capital equipment orders hit a 5-year high, but revenue declined due to delayed deliveries. The BioLife acquisition is expected to be $0.05 accretive to 2027 earnings. Management forecasts 2027 revenue exceeding $1B and narrowed 2026 organic growth to 12%-13%. China grew over 40%, and the Analytics franchise set records.

finance.yahoo.com2 min
OCT 27
$RGENMedAI 8/10

Repligen (RGEN) Q3 2026 Earnings Call Transcript

Repligen reported $209M in Q3 2026 revenue, up 12.5% organically, with expanded margins. The company raised full-year guidance, including $24M from BioLife acquisition. Capital equipment orders rose mid-teens YoY, and services grew over 20%. Biopharma drove growth, while CDMOs declined. Repligen expects to exceed $1B in revenue in 2027, with Asia Pacific showing strong growth.

finance.yahoo.com2 min
OCT 27
$RGENMedAI 8/10

What Repligen (RGEN) Said on Its Q3 Earnings Call

Repligen (RGEN) reported Q3 earnings, noting BioLife acquisition will be slightly dilutive to Q4 earnings but expects $0.05 EPS accretion by 2027. Equipment orders rose mid-teens YoY, with a strong backlog for 2027. Filtration revenue fell 11%, while consumables and services grew over 20%. Chromatography and proteins revenue surged over 50% and 40%, respectively. Adjusted EPS rose 15% to $0.53. Repligen expects 2027 revenue growth of at least 25%, exceeding $1B.

finance.yahoo.com2 min